Arterex - Global Medical Device Contract Manufacturing Leader

admin72026-04-17 10:25:52

📢 Important Milestones (January 2026):
Arterex completed the acquisition of Synecco, an Ireland-based end-to-end development and contract manufacturing leader, and unveiled a unified brand identity across North America, consolidating all North American operating divisions under the Arterex name while European divisions retain their established local brand identities.

Company Overview (Updated April 2026)

Arterex is a premier global contract development and manufacturing organization (CDMO) headquartered in Scottsdale, Arizona. Founded in November 2022 by Investindustrial, a leading European independent investment group, Arterex has Rapidly established itself as a comprehensive manufacturing partner for medical device and life sciences companies worldwide.

Mission: To provide diversified, high-precision manufacturing solutions that enable medical device innovators to bring life-changing technologies to market efficiently, while maintaining the highest standards of quality, regulatory compliance, and customer collaboration.

Corporate Evolution and Strategic Expansion (2022-2026)

Formation and Founding (November 2022)

Arterex was created through the combination of four complementary companies:

- Formula Plastics Inc. (North America)

- Kabo S.r.l. (Italy)

- Luc & Bel S.r.l. (Italy)

- ModenPlast S.r.l. (Italy)

Strategic Acquisitions (2023-2026)

2023:

- June 2023: Acquired NextPhase Medical Devices LLC, a Class II and III medical device contract manufacturer specializing in complex electromechanical devices and active implantables, doubling the size of the Group

2024:

- January 2024: Acquired Micromold, Inc. (Riverside, CA), a precision micromolding specialist with 40+ years of expertise; operations relocated to Tecate, Mexico facility

2025:

- January 2025: Acquired Phoenix S.r.l. (Modena, Italy), expanding medical device development, assembly, and packaging capabilities in Europe with ISO 8 clean rooms

- February 2025: Acquired Adroit USA Inc. (Pleasanton, CA), adding two ISO 13485-certified manufacturing facilities in Bangalore, India, with 650+ employees specializing in high-precision injection molding, stainless steel, and nitinol components

- July 2025: Acquired Xponent Global, Inc. (Massachusetts), an ISO 9001:2015 certified producer of extruded tubing since 1937, adding 8 extrusion lines and 5,000 ft² of Class 8 cleanroom space

2026:

- January 6, 2026: Acquired Synecco (Galway, Ireland), adding end-to-end product development expertise in advanced medical delivery systems and structural heart devices

- January 20, 2026: Unified North American brand identity across all operating divisions

North America Brand Unification (January 2026)

Strategic Rationale:

- North America: All operating divisions transitioned to operate under the unified Arterex name and visual identity to simplify engagement, strengthen brand recognition, and reinforce Arterex's position as a cohesive, end-to-end partner

- Europe: Italy- and Ireland-based operating companies (including Phoenix and Synecco) retain their established local brand identities, reflecting their deep regional heritage, longstanding customer relationships, and strong regulatory reputations

Customer Commitment: Whether operating under the Arterex name or long-established local brands, every customer receives the same commitment to quality, innovation, and collaboration backed by the full strength of Arterex's global platform.

Core Capabilities and Services

Manufacturing Expertise

Arterex provides comprehensive manufacturing solutions across the entire product lifecycle:

- Product Design & Development: Concept design, engineering, rapid prototyping, 3D printing, and design for manufacturability

- Materials & Compounding: Custom material formulation and compounding services

- Extrusion: Medical tubing including multi-lumen, taper tubing, para tubing, radiopaque filaments, and tight tolerance single lumen tubing (expanded through Xponent Global acquisition)

- Injection Molding: High-precision plastic components, micro-molding (10-33 ton machines), insert molding, and overmolding

- Metals Processing: Precision stainless steel and nitinol components, metal fabrication, and machining capabilities (added through Adroit USA acquisition)

- Advanced Assembly: Class I, II, and III disposable devices, electromechanical devices, RF bag welding, IV therapy components, and implantable devices

- Tooling & Mold Building: In-house mold design, fabrication, and maintenance

- Packaging & Sterilization: Finished device assembly, packaging, and supply chain integration

Regulatory & Quality Standards

- ISO 13485:2016 certification across facilities

- FDA-registered manufacturing facilities

- EU MDR (Medical Device Regulation) compliance for European operations

- ISO 8 cleanroom manufacturing capabilities (over 830,000 sq ft total manufacturing space with 24 clean rooms)

Global Manufacturing Footprint (2026)

Scale:

- Facilities: 16 state-of-the-art manufacturing facilities

- Continents: 4 (North America, Europe, Asia, Africa)

- Countries: United States, Mexico, Italy, Ireland, Egypt, India

- Employees: 2,100+ professionals worldwide

- Manufacturing Space: 830,000+ sq ft with 24 clean rooms

Leadership Team

Executive Leadership

Executive Chairman: Charles Stroupe

- Co-founded and led Medegen through its sale to Carefusion (NYSE: CFN) in 2010

- Co-founded and led Providien through its sale to Carlisle Companies (NYSE: CSL) in 2019

- Senior leadership team has worked together building successful medical device contract manufacturing companies for nearly 30 years

Chief Executive Officer: Jeff Goble / Jeffery Goble

- Leading Arterex through global expansion and brand unification

- Previously led Providien as CEO through its successful exit

Chief Financial Officer: Paul Jazwin

- Co-founded Medegen and Providien with Stroupe and Goble

President, North America: Bill Gerard

- Oversees North American operations and integration of acquired companies

Customer Base and Market Position

Target Customers:

- Blue-chip global MedTech OEMs

- Leading medical device innovators and startups

- Companies seeking alternatives to China-based manufacturing (Adroit USA provides cost-effective, high-tech Asian production source)

Revenue Distribution: Approximately 70% generated in the United States

End Markets: Cardiovascular, structural heart, neurological, laparoscopic, dental, diagnostic, and general surgery devices

Recent Developments and Expansion (2026)

Massachusetts Manufacturing Expansion (April 2026)

Arterex expanded manufacturing capabilities at its Massachusetts facility (Xponent Global), adding capacity to serve North American extrusion needs locally at the highest global industry standards.